Evotec Forms Drug Discovery Collaboration with UCB

Evotec AG has entered into a multi-target drug discovery collaboration with UCB in the field of immunology.

Evotec AG announced Wednesday that it has entered into a multi-target drug discovery collaboration with UCB in the field of immunology.

According to the collaboration, Evotec will apply its drug discovery expertise to identify small molecules against a selected number of targets, then optimize a preclinical candidate. Evotec will receive research funding and will receive early stage discovery, preclinical and clinical milestones, as well as royalties on sales of any approved drugs from the collaboration.

Dr. Werner Lanthaler, chief executive officer of Evotec, said, "We are extremely pleased that UCB has again selected Evotec to collaborate on this second significant Drug Discovery Collaboration. This integrated drug discovery deal showcases our